Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurokinin B (NKB) is a decapeptide member of the tachykinin family encoded by the TAC3 gene in humans. It acts primarily as an endogenous agonist at the Neurokinin 3 receptor (NK3R), which belongs to the G protein-coupled receptor superfamily. NKB plays critical roles in neuronal excitation, smooth muscle contraction, vasodilation, and especially regulation of gonadotropin-releasing hormone secretion—a key process for normal reproductive function. Mutations affecting either NKB or its receptor can result in hypogonadotropic hypogonadism due to impaired GnRH release. Elevated levels have been implicated in pre-eclampsia during pregnancy. While not itself targeted by drugs, modulation of its signaling through NK3R antagonists has been explored therapeutically for conditions such as menopausal hot flashes and psychiatric disorders.
Not applicable for drugs targeting NKB directly. For NK3R antagonists/agonists: - Blockade or activation of G protein-coupled signaling pathways downstream of the Neurokinin 3 receptor
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurokinin B (NKB).